# Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT07687459** · PHASE3 · RECRUITING · sponsor: **InSilico Medicine Hong Kong Limited** · enrollment: 320 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** INS018_055 tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07687459
- **Lead sponsor:** InSilico Medicine Hong Kong Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-09
- **Primary completion:** 2029-10-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687459, "Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*